WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript Summary

moomoo AIApr 29 02:38 ET · Conference Call

WUXI APPTEC: Q1 net profit significantly increased, maintaining double-digit growth guidance for the year | Interpretations

① WUXI APPTEC's Q1 net income attributable to the parent company grew 89.1% year-on-year, mainly due to revenue growth, improved overall profitability, and the sale of WUXI XDC stocks; ② WUXI APPTEC still believes it can achieve its annual double-digit growth target.

cls.cnApr 28 09:31 ET

WUXI APPTEC: Q1 revenue of 9.655 billion yuan, a year-on-year growth of 21%, with strong performance in the Business driving significant growth.

WUXI APPTEC's first quarter of 2025: strong performance growth driven by the chemical Business, TIDES Business revenue surged by 187%. Key financial highlights...

wallstreetcnApr 28 05:15 ET

Bide Pharmaceutical's net profit in 2024 increased by 7.17% year-on-year, with the Overseas market becoming the growth engine.

In 2024, Bid achieved an annual revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; the net income attributable to the parent company's shareholders was 0.117 billion yuan, a year-on-year increase of 7.17%; the company stated it will continue to optimize the product structure, deepen its global layout, and increase R&D investment to respond to changes in the industry technology.

cls.cnApr 24 00:29 ET

Shanghai Medicilon Inc.'s revenue in 2024 declined by over 20%, with losses further expanding.

① Affected by multiple factors such as the slowdown in investment and financing in the Industry, intensified market competition, and contraction in domestic market demand, Shanghai Medicilon Inc. is expected to continue expanding its losses to 0.331 billion yuan in 2024; ② By region, the domestic market is heavily impacted by the reduction in R&D investment from local pharmaceutical companies and price wars, becoming the main drag on performance; the Overseas market, although maintaining growth, has seen increased costs due to new experimental facility investments, squeezing profit margins.

cls.cnApr 21 11:11 ET

The Equity Transfer of the symbol has not been delivered, and Bidu Medicine terminates the significant Assets reorganization.

① Regarding the termination of the merger and acquisition, the company stated that the failure to complete the delivery of 100% equity of the target company as expected has resulted in the inability to achieve the purpose of this Trade. Liu Weidong stated that the termination of this acquisition will not affect the company's established Global Strategy layout; ② Bid Pharma has completed the construction of the R&D center and the upgrade of storage facilities in the USA market last year.

cls.cnApr 15 08:33 ET